Clinical trial NCT05758896: Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
Official title: Effect on Contrast Induced Acute Kidney Injury of APX-115 in Subjects Undergoing Percutaneous Coronary Intervention A Randomized, Double-blind, Parallel Group, Multicenter, Multi-national Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Contrast Induced Acute Kidney Injury
Keywords: Isuzinaxib
APX-115
Contrast media
ROS
Acute Kidney Injury
Percutaneous Coronary Intervention
Lead sponsor: Aptabio Therapeutics, Inc.
Sponsor class: INDIV
First posted: 2023-03-08
Enrollment: 280
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 280 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.

Detailed description: Patients with chronic kidney disease undergoing percutaneous coronary intervention deserve careful consideration of various clinical options to minimize the risk of contrast-induced acute kidney injury and to optimize clinical outcomes. Contrast-induced acute kidney injury (CI-AKI) is a leading cause of a hospital-acquired renal failure and has been reported to affect both the mortality and morbidity of patients receiving contrast media. Contrast-induced acute kidney injury is the third leading cause of hospital-acquired acute kidney injury and has been recognized as a serious complication of percutaneous coronary intervention (PCI), which may be associated with increased morbidity and mortality.

APX-115 is a potent small molecule inhibitor of NADPH-oxidase (NOX) isozymes developed by AptaBio Therapeutics, Inc. In-vivo study results suggest that multiple NOX isoforms may contribute to renal injury in CI-AKI model, and pan-NOX inhibition may be a new therapeutic approach for prevention of CI-AKI.

Eligibility criteria: Inclusion Criteria:

1. Willing and able to provide informed consent.
2. Male or female, of any race or ethnicity, 18 years of age or older, inclusive, on the day of informed consent. Racial and ethnic minorities should be included in the study population to the greatest extent possible.
3. Diagnosed with coronary artery disease.
4. Planned to undergo coronary angiography within 4 weeks of being consented.
5. Risk of CKD evidenced by 30 mL/min/1.73m2 ≤ eGFR (Glomerular filtration rate) \< 90 mL/min/1.73 m2 confirmed by local or central laboratory.
6. Women of childbearing potential or males willing and able to use at least one protocol-specified method of contraception for the duration of their enrolment.
7. Subject is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the ICF.

Exclusion Criteria:

1. Females who are pregnant or who are planning to become pregnant before the end of planned enrolment or who are breastfeeding.
2. Subjects who are not expected to go through PCI at the discretion of investigator or cardiologist
3. Subjects who have a history of hypersensitivity to contrast media or who cannot be administered contrast media according to investigator's discretion
4. Acute myocardial infarction within 1 month prior to Screening
5. ESRD confirmed by eGFR \< 15 mL/min/1.73 m2 at Screening.
6. Clinically significant heart disease as determined by the Investigator within 2 months prior to Screening including but not limited to any of following; cardiogenic shock, treatment requiring intra-aortic balloon pump (IABP) support, treatment with extra corporeal membrane oxygenation (ECMO), or NYHA class IV heart failure.
7. Uncontrolled treated/untreated hypertension (defined as systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg, mean of measured 2 times at Screening will be permitted).
8. Known or suspected hypersensitivity to any component of the APX-115 formulation.
9. History of acute kidney injury or renal dialysis within 1 month prior to Screening and/or plan to undergo a renal dialysis during enrolment.
10. Clinically apparent liver disease as determined by the Investigator (e.g., jaundice, cholestasis, hepatic synthetic impairment, or active hepatitis) or moderate or severe hepatic impairment as determined by Child-Pugh score (Class B or C) at Screening.
11. Impaired liver function, defined as alanine aminotransferase (ALT) ≥ 2.5 times UNL or Total bilirubin \>1.5 × ULN, unless the subject has known Gilbert's syndrome.
12. Any sign or symptom of acute or chronic infection at Screening.
13. Receipt of any investigational drug within 4 weeks prior to Screening.
14. Confirmed or suspected abuse of alcohol or controlled substances within 1 year prior to Screening.
15. Clinically significant hematology abnormalities; hemoglobin \<9 g/dL for females or \<11 g/dL for males, absolute neutrophil count \<1500/mm3, platelet count \<100 × 109/L) at Screening. If any parameter is below the specified threshold, one hematology retest analyzed at the central or local laboratory within a week prior to randomization is permitted with the result of the last sample being conclusive.
16. Any other clinically significant medical condition or laboratory abnormality as determined by the Investigator that might jeopardize the safety of the subject, impair subject compliance, or impede safety/efficacy observations during enrolment.
17. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation with protocol requirements
18. Use of CYP1A2, CYP2B6 and CYP3A4 substrates or UGT inhibitors and inducers or OAT3 substrates prior to enrollment or concurrently. It will be only accepted to be eligible to screening if the subjects' concomitant medications will be reviewed and approved by the medical monitor and/or sponsor prior to the initial study dose

Primary outcomes:
measure: Safety endpoints: adverse event
timeFrame: Day -2 to day 84
measure: Safety endpoints: vital sign
timeFrame: Day 0 to day 84
measure: Safety endpoints: physical exam
timeFrame: Day 0 to day 84
measure: Safety endpoints: ECG
timeFrame: Day 0 to day 84
measure: Safety endpoints: labs
timeFrame: Day 0 to day 84
Secondary outcomes:
measure: Incidence rate of Acute kidney injury
timeFrame: from baseline up to 72 hours after PCI procedure
measure: Long term kidney function: Serum creatinine
timeFrame: week 4 and week 12
measure: Long term kidney function: eGFR
timeFrame: week 4 and week 12
measure: Kidney function parameters: creatinine, BUN
timeFrame: over 12-week period
measure: Kidney function parameters: eGFR
timeFrame: over 12-week period
measure: pharmacokinetics parameters: the area under the plasma concentration-time curve (AUC0-last, AUCtau)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: peak concentration (Cmax, Tmax)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: steady state peak plasma concentration (Css,max)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: steady state trough plasma concentration (Css,min)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: steady state after 5 consecutive days of drug administration
timeFrame: Day -2~2
measure: pharmacokinetics parameters: apparent total clearance (CL/F)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: renal clearance (CLR)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: apparent nonrenal clearance (CLNR/F)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: apparent volume of distribution (V/F)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: terminal half-life (t1/2)
timeFrame: Day -2~2
measure: pharmacokinetics parameters: fraction/cumulated fraction of excreted in urine
timeFrame: Day -2~2
Other outcomes:
measure: Biomarkers assessment
timeFrame: 72 hours
measure: Composite PCI outcome
timeFrame: over 12-week period
Locations:
city: Hialeah
country: United States
facility: Florida Cardiovascular Research
state: Florida
city: Ocala
country: United States
facility: Sarkis Clinical Trials
state: Florida
city: Chuncheon
country: Korea, Republic of
facility: Kangwon National University Hospital
city: Daegu
country: Korea, Republic of
facility: Keimyung University Dongsan Hospital
city: Daejeon
country: Korea, Republic of
facility: Chungnam National University Hospital
city: Goyang
country: Korea, Republic of
facility: Inje University Ilsan Paik Hospital
city: Gwangju
country: Korea, Republic of
facility: Chonnam National University Hospital
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea Seoul St. Mary's Hospital
city: Suwon
country: Korea, Republic of
facility: The Catholic University of Korea St. Vincent's Hospital
city: Ulsan
country: Korea, Republic of
facility: Ulsan University Hospital
Study officials:
References: